Digital health revolution: Is it time for affordable remote monitoring for Parkinson's disease?

Frontiers in Neurology

Volumn 6, Issue FEB, 2015, Pages

  Papapetropoulos, Spyros ^a,b   Mitsi, Georgia ^c   Espay, Alberto J ^d  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c Apptomics LLC   (United States)

^d UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Digital health; Disease management; Health outcomes; Parkinson's disease; Remote monitoring

Indexed keywords

LEVODOPA;

AGE; CLINICAL ASSESSMENT; CLINICAL FEATURE; COMPUTER PROGRAM; DYSKINESIA; DYSTONIA; ECONOMIC ASPECT; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH SERVICE; HUMAN; MEASUREMENT PRECISION; MEDICAL DECISION MAKING; MEDICAL INFORMATION SYSTEM; PARKINSON DISEASE; PATIENT MONITORING; PREVALENCE; RATING SCALE; REVIEW; SOCIAL ASPECT;

EID: 84926333326     PISSN: None     EISSN: 16642295     Source Type: Journal    
DOI: 10.3389/fneur.2015.00034     Document Type: Review

References (25)

1. Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology (2007) 68(5):384-6. doi: 10.1212/01.wnl.0000247740.47667.03
2. Kowal SL, Dall TM, Chakrabarti R, Storm MV, Jain A. The current and projected economic burden of Parkinson's disease in the United States. Mov Disord (2013) 28(3):311-8. doi:10.1002/mds.25292
3. Fahn S. Description of Parkinson's disease as a clinical syndrome. Ann N Y Acad Sci (2003) 991:1-14. doi:10.1111/j.1749-6632.2003.tb07458.x
4. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol (1999) 56(1):33-9. doi:10.1001/archneur.56.1.33
5. Gallagher DA, Schrag A. Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease. CNS Drugs (2008) 22(7):563-86. doi:10.2165/00023210-200822070-00003
6. Schrag A, Banks P. Time of loss of employment in Parkinson's disease. Mov Disord (2006) 21(11):1839-43. doi:10.1002/mds.21030
7. Martinez-Martin P, Serrano-Duenas M, Forjaz MJ, Serrano MS. Two questionnaires for Parkinson's disease: are the PDQ-39 and PDQL equivalent? Qual Life Res (2007) 16(7):1221-30. doi:10.1007/s11136-007-9224-2
8. World Health Organization. Neurological Disorders: A Public Health Approach: Parkinson's Disease. Geneva: WHO Press (2006).
9. Dewey RB Jr. Management of motor complications in Parkinson's disease. Neurology (2004) 62(6 Suppl 4):S3-7. doi:10.1212/WNL.62.6_suppl_4.S3
10. Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology (2009) 72(21 Suppl 4):S1-136. doi:10.1212/WNL.0b013e3181a1d44c
11. Nutt JG. Levodopa-induced dyskinesia: review, observations, and speculations. Neurology (1990) 40(2):340-5. doi:10.1212/WNL.40.2.340
12. Jankovic J. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov Disord (2005) 20(Suppl 11):S11-6. doi:10.1002/mds.20458
13. World Health Organization. Atlas: Country Resources for Neurological Disorders. Geneva: WHO Press (2004).
14. Fahn S, Elton RL, Members UP. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB, editors. Recent Developments in Parkinson's Disease. (Vol. 2), Florham Park, NJ: Macmillan Healthcare Information (1987). p. 153-63. 293-304.
15. Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement disorder society-sponsored revision of the unified Parkinson's disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord (2008) 23(15):2129-70. doi:10.1002/mds.22340
16. Papapetropoulos S, Jagid JR, Sengun C, Singer C, Gallo BV. Objective monitoring of tremor and bradykinesia during DBS surgery for Parkinson disease. Neurology (2008) 70(15):1244-9. doi:10.1212/01.wnl.0000308936.27780.94
17. Hauser RA, Hsu A, Kell S, Espay AJ, Sethi K, Stacy M, et al. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial. Lancet Neurol (2013) 12(4):346-56. doi:10.1016/S1474-4422(13)70025-5
18. Biglan KM, Voss TS, Deuel LM, Miller D, Eason S, Fagnano M, et al. Telemedicine for the care of nursing home residents with Parkinson's disease. Mov Disord (2009) 24(7):1073-6. doi:10.1002/mds.22498
19. Dorsey ER, Deuel LM, Voss TS, Finnigan K, George BP, Eason S, et al. Increasing access to specialty care: a pilot, randomized controlled trial of telemedicine for Parkinson's disease. Mov Disord (2010) 25(11):1652-9. doi:10.1002/mds.23145
20. Samii A, Ryan-Dykes P, Tsukuda RA, Zink C, Franks R, Nichol WP. Telemedicine for delivery of health care in Parkinson's disease. J Telemed Telecare (2006) 12(1):16-8. doi:10.1258/135763306775321371
21. Maetzler W, Domingos J, Srulijes K, Ferreira JJ, Bloem BR. Quantitative wearable sensors for objective assessment of Parkinson's disease. Mov Disord (2013) 28(12):1628-37. doi:10.1002/mds.25628
22. Dolan B. 2016: 3M patients monitored over cellular networks. Mobile Health News [Internet]. (2012). Available from: http://mobihealthnews.com/16162/2016-3m-patients-monitored-over-cellular-networks/
23. Comstock J. Remote patient monitoring to save $36B by 2018. Mobile Health News [Internet]. (2013). Available from: http://mobihealthnews.com/23880/remote-patient-monitoring-to-save-36b-by-2018/
24. Montini L. VA Plans to Eliminate Telehealth Co-Pays. Health 20 [Internet]. (2012). Available from: http://www.health2con.com/news/2012/04/10/va-plans-to-eliminate-telehealth-co-pays/
25. Dorsey ER, Venkataraman V, Grana MJ, Bull MT, George BP, Boyd CM, et al. Randomized controlled clinical trial of "virtual house calls" for Parkinson disease. JAMA Neurol (2013) 70(5):565-70. doi:10.1001/jamaneurol.2013.123